Viking Therapeutics, Inc. - Common Stock (VKTX)

Viking Therapeutics' promising weight loss drug could revolutionize the obesity market and propel the company's stock price to new highs.

Viking Therapeutics Inc. (NASDAQ: VKTX) has surged 238% year-to-date and 326% over the past year, far outpacing its sector and market.

Viking Therapeutics stock soars on clinical trial results and a solid earnings beat, signaling a potential market shake-up in the biopharmaceutical sector.

Global pharmaceutical company Eli Lilly & Co. (NYSE: LLY) has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been

Viking Therapeutics, Inc. (NASDAQ: VKTX) is the focus of IBN’s latest stock spotlight. The company’s shares have moved 4.46% on the day to $25.43.

Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases

Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy

Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound.

Eli Lilly stock continues to move higher after the company reported continuing momentum for its flagship GLP-1 weight loss drugs

The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolio

Altimmune has a GLP-1 candidate in Phase 2 trials, but the company continues to burn cash and may need a big pharma partner to get its drug to market

Equities lost ground this week as investors consider the effect of fewer rate cuts, rising oil prices, and robust job gains ahead of a new earnings season

Viking Therapeutics is preparing to be the next entry into the GLP-1 Market, and VKTX stock is soaring as analysts start to bid the stock higher

The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.

The Ozempic craze continues to make headlines in the medical sector, and GLP-1 drug stocks such as Vivani Medical continue to surge higher

Viking Therapeutics, Inc. (NASDAQ: VKTX) is one today’s most active stocks by volume. So far today, approximately 17.45M shares of Viking Therapeutics, Inc. have been exchanged, as compared to an average 30-day volume of 4.02M shares.

Clinical weight-loss medications have been making headlines as GLP-1 drugs like Novo Nordisk A/S (NYSE: NVO) owned Ozempic and Wegovy and Eli Lilly and Co.

EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END

A bid to acquire Versanis boosts Eli Lilly & Co. by 2.80% in the past week, as the competition to develop the most effective weight-loss drug intensifies.

The topic of weight loss drugs has been making recent headlines. The positive phase 1 clinical trial for Viking Therapeutics Inc. (NASDAQ: VKTX) GLP-1 treatme

Shares of Viking Therapeutics, Inc. (NASDAQ: VKTX) traded at a new 52-week high today and are currently trading at $14.99. So far today, approximately 48.12M shares have been exchanged, as compared to an average 30-day volume of 2.64M shares.

Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP

VKTX stock is young but strong and they have excellent potential, particularly following successful trial results from Madrigal Pharma's recent drug trial.